This Viewpoint discusses the US Food and Drug Administration’s authority to require drug and device sponsors to submit diversity action plans and policy gaps that limit the organization’s ability to achieve demographic representation in clinical trials.
No takes yet. Share an insight, caveat, or question.
Varma et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: